Postoperative Inflammation

Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery is now commercially available in the U.S., according to a press release from Eyenovia.

Modern-day cataract surgery has a high success and safety record, with the vast majority of patients having a smooth postop recovery.

A pooled post hoc analysis of phase 3 studies showed rapid and consistent efficiency of Dextenza in the treatment of post-cataract inflammation and pain.

EyePoint Pharmaceuticals and ImprimisRx have signed a commercial alliance regarding promotion of Dexycu in the United States, according to a press release.

Consistent and comprehensive communication between optometrists and ophthalmologists will always be the key to successful comanagement of cataract patients.

The world of perioperative medications associated with cataract surgery for the premium surgeon is evolving rapidly.

Adults with type 2 diabetes who undergo surgery need more insulin following surgery, particularly if they experience increased C-reactive protein level or HbA1c, according to findings published in the Journal of Diabetes Investigation.

EyePoint Pharmaceuticals and Ocumension Therapeutics have signed an exclusive license agreement for the development and commercialization of Dexycu in mainland China, Hong Kong, Macau and Taiwan, according to a press release.

ORLANDO, Fla. – Results from three vehicle-controlled phase 3 studies indicated that Dextenza was easy to insert and monitor and was well-accepted by patients.